Point Man On Protein Science

Harvard Researcher Timothy Springer’s Lifetime Of Advocacy For An Essential – But Often Neglected – Driver of New Drug Development

In this latest edition of the Lab Links series on notable figures responsible for major advances in drug discovery, In Vivo talks to Harvard Medical School professor and biologist Timothy Springer on his 50-year record as an academic scientist, business entrepreneur and philanthropist. His latest venture is being co-founder – and principal funder – of the independent non-profit Institute for Protein Innovation, an institution designed to fill a critical niche in open-source biomedical research.

Springer_Timonthy_1200.jpg
"Mentorship is one of the most important ways of ensuring great science continues to grow." - Timothy Springer

As an academic biochemist, Timothy Springer has authored original insights on the structure, function and interactions of biomedically important proteins: one 1990 paper, on the cell recognition molecules that drive immune response, has been cited in peer review more than 10,000 times. His work has shaped medical practice in key fields like immunology, inflammation, hematology and infectious diseases, accomplishments reflected in the clinic through at least four blockbuster drugs, all now available to patients worldwide. Though a skeptic at first, Springer has also emerged as a savvy start-up entrepreneur, earning outsize returns as a founder and investor in seven biotech companies, gains he has now applied as an advocacy philanthropist testing new business models to plug research silos, address unmet medical needs and promote the open-source dissemination of knowledge.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Leadership

More from In Vivo

Podcast: Ochre Bio’s Approach To Precision Medicine In Liver Treatment

 
• By 

Ochre Bio co-founder and CSO Quin Wills spoke with In Vivo about the UK-based company's novel approach to finding RNA therapies for chronic liver disease.

Richard DiMarchi On The GLP-1 Revolution: An Overnight Success After 40 Years

 

As GLP-1 agonists surge to blockbuster status transforming diabetes and obesity treatment, Richard DiMarchi, the pioneering scientist behind their development, recounts the inside story of the drug class in a fireside chat.

Rising Leaders 2025: João Ribas On Building At The Intersection Of Science And Business

 
• By 

João Ribas combines scientific expertise with venture capital at Novo Holdings, applying his dual background to develop biotech investments that connect academic research with commercial opportunity.